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Introduction 
Implantable cardioverter defibrillator (ICD) therapy has been shown 
to reduce the risk of sudden cardiac death (SCD) and improve sur-
vival in severe heart failure.
1-3) The Multicenter Automatic Defibril-
lator Implantation Trial II (MADIT-II) showed a benefit of ICD ther-
apy in patients with prior myocardial infarction (MI) and advanced 
left ventricular dysfunction.
4)5) The Defibrillators in the Non-ischemic 
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Background and Objectives: Implantable cardioverter defibrillator (ICD) therapy is recommended as the primary tool for prevention of 
sudden cardiac death (SCD) in symptomatic patients with severe left ventricular dysfunction. There is a paucity of information on wheth-
er this recommendation is appropriate for the Korean population with severe heart failure.
Subjects and Methods: The study group consisted of 275 consecutive patients (mean age 65 years, 71% male) who met the ICD implan-
tation criteria for primary prevention (left ventricular ejection fraction ≤30% and New York Heart Association functional class II or III). We 
analyzed the clinical characteristics and outcomes of an ischemic cardiomyopathy (ICMP) group (n=131) and a non-ischemic cardiomyopa-
thy (NICMP) group (n=144). The outcomes of these 2 groups were compared with the Multicenter Automatic Defibrillator Implantation Trial 
II (MADIT-II) conventional and Defibrillators in the Non-ischemic Cardiomyopathy Treatment Evaluation (DEFINITE)  standard therapy groups, 
respectively.
Results: Eighty patients (29%) died during a follow-up period of 40±17 months. The NICMP group had better all-cause mortality rates than 
the ICMP group (19% vs. 40%, p<0.001), however both groups had a similar incidence of SCD (7% vs. 10%, p=0.272). The 2-year all-cause 
mortality and SCD for the ICMP group were similar to those of the MADIT-II conventional therapy group (20% vs. 20%, 7% vs. 10%, re-
spectively, all p>0.05). All-cause mortality and the incidence of SCD in the NICMP group were comparable to those of the DEFINITE stan-
dard therapy group (13% vs. 17%, 6% vs. 6%, respectively, all p>0.05). 
Conclusion: Korean patients with severe heart failure in both the ICMP and NICMP groups had all-caused mortality and risk of SCD com-
parable to patients in the MADIT-II and DEFINITE standard therapy groups. Therefore, the primary prevention criteria for ICD implantation 
would be appropriate in both Korean ICMP and NICMP patients. (Korean Circ J 2012;42:173-183)
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Cardiomyopathy Treatment Evaluation (DEFINITE) trial reported that 
ICD reduced the risk of SCD from arrhythmia in severe, non-isch-
emic cardiomyopathy (NICMP).
6) Based on these trials, the American 
College of Cardiology/American Heart Association/Heart Rhythm So-
ciety has recommended prophylactic ICD implantation as the primary 
intervention to prevent SCD in patients with severe heart failure.
7) 
Although Asian populations are known to have lower risks of SCD 
compared to Caucasians, there is a paucity of data on whether pro-174  Implantable Cardioverter Defibrillator Implantation
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phylactic ICD therapy has a beneficial effect on preventing SCD in 
Asian populations with heart failure.
8) Japanese patients who met 
the MADIT-II criteria showed better survival rates than those of the 
MADIT-II conventional therapy group.
9) Recently, Chinese patients 
with the same inclusion criteria as MADIT-II showed a similar cumula-
tive probability of SCD to that of the MADIT-II conventional therapy 
group.
10) However, there are few studies reporting the prognosis of 
NICMP in an Asian population. Therefore, the aims of this study 
were to investigate the clinical outcome of Korean patients with 
severe heart failure and who were candidates for ICD implantation 
as a primary prevention against SCD, and to compare those results 
with data from the conventional therapy groups in the previous 
MADIT-II and DEFINITE trials.
Subjects and Methods
Study population
A group of 588 consecutive patients who had ≤30% of left ven-
tricular ejection fraction (LVEF) on echocardiography at Seoul Na-
tional University Hospital from January 2003 to December 2006 
were retrospectively enrolled. The cause of cardiomyopathy was 
evaluated and classified as follows: ischemic cardiomyopathy (ICMP) 
was defined as left ventricular dysfunction associated with coro-
nary artery disease (>50% narrowing of the diameter of at least 
one of the 3 major coronary arteries on coronary angiography), a 
history of a MI, a regional wall motion abnormality in the echocar-
diography, abnormal perfusion in single photon emission comput-
erized tomography, or a Q wave in the electrocardiogram.
11) NICMP 
was defined as left ventricular dysfunction without a definite cause 
by coronary lesion.
11) In patients with acute MI, echocardiography 
data were used, which was measured at least 40 days after MI. Only 
those with NICMP and whose LV systolic function was ≤30% after 
3 months of medical therapy were included. Patients excluded from 
the study included those who did not have LVEF data after stabiliz-
ation or had not been followed-up in an outpatient clinic for at le-
ast 3 months after appropriate medical therapy (n=81), those with 
an improved LVEF of >30% after medical therapy or a transient he-
art failure state due to uncontrolled tachyarrhythmia, sepsis, drug 
or other causes (n=171), and those who expired before discharge 
(n=54). Two patients with New York Heart Association (NYHA) func-
tional class (Fc) I and 1 patient with a previously inserted ICD were 
excluded, and 4 patients who had undergone heart transplantation 
after severe heart failure were also excluded. Finally, 275 patients 
with severe left ventricular dysfunction with NYHA Fc II or III were 
enrolled. A cohort of 131 patients was classified as the ICMP group, 
and 144 patients were classified as the NICMP group. The institutio-
nal review board approved the study protocol. 
Risk factor assessment
Basic demographic data were reviewed from the medical records. 
Data concerning atrial fibrillation (AF), hypertension, diabetes mel-
litus, chronic kidney disease, and valvular heart disease were syste-
matically acquired. AF was diagnosed based on electrocardiography 
or a past medical history of AF treatment. Patients who had been 
previously diagnosed with hypertension and taken antihypertensive 
medicine were defined as hypertension patients. Patients with dia-
betes mellitus were defined as those who had been diagnosed by a 
fasting plasma glucose ≥126 mg/dL, plasma glucose ≥200 mg/dL 
2 hours after taking 75 g of oral glucose, or symptoms of hypergly-
cemia and casual plasma glucose ≥200 mg/dL. Patients with a glo-
merular filtration rate <60 mL/min/1.73 m
2 were diagnosed with 
chronic kidney disease. Patients with valvular heart disease were 
defined as those with stenotic valvular disease or valvular regurgit-
ation at more than a moderate degree on the echocardiography. In-
formation on prescribed medication which was used for >3 months 
during the follow-up period such as beta-blockers, angiotensin-con-
verting-enzyme inhibitors (ACEIs), angiotensin II receptor blockers 
(ARB), amiodarone, digitalis, HMG-CoA reductase inhibitors, loop 
diuretics, potassium sparing diuretics, thiazide, anti-platelet drugs, 
or anti-coagulation drugs was collected. Modes of revascularization 
methods were classified as percutaneous coronary intervention (PCI), 
coronary artery bypass surgery (CABG), both PCI and CABG, or 
thrombolysis therapy.
Clinical outcomes
Follow-up data were obtained from hospital records, by telephone 
contact with family members, and from death certificates obtained 
from the National Statistical Office (NSO). Deaths were categorized 
by their causes, including SCD, non-SCD, unclassified cardiac death, 
non-cardiac death, and death from unknown causes. For in-hospital 
deaths, SCD was assigned according to hospital records by an at-
tending physician or by evidence of an arrhythmic event, such as ven-
tricular tachycardia or ventricular fibrillation.
12) For out-of-hospital 
deaths, we obtained follow-up data by telephone contact with fa-
mily members. Patients who experienced SCD were defined as those 
who died suddenly and unexpectedly within 1 hour of cardiac symp-
toms in the absence of progressive cardiac deterioration, those who 
died unexpectedly in bed during sleep, and those who died unex-
pectedly within 24 hours after last being seen alive.
5)12) We used 
the database of Korean Standard Classification of Diseases from 
the NSO to classify those who could not be identified by the above 
2 methods. Unclassified cardiac death was defined as cases in wh-
ich the clinical information was inadequate to classify the cardiac 
deaths as sudden or non-sudden. Patients were followed until De-
cember 2008. 175 JiYeong Kim, et al.
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Statistical analysis
Continuous variables were expressed as the mean±SD, whereas 
categorical variables were presented as absolute values and per-
centages. Student t-tests were used to analyze continuous vari-
ables and chi-square tests were used for categorical variables. The 
log-rank test was used to compare Kaplan-Meier survival curves, 
and the Cox proportional-hazards model was used to adjust for co-
variates and to estimate the hazard ratio (HR) for death and the 
corresponding 95% confidence interval (CI). Survival tables obtain-
ed from the Kaplan-Meier analysis were used to compare the ICMP 
group to the MADIT-II trial group and the NICMP group to the DEFI-
NITE trial group.
A standard normal distribution was used to compare the survival 
rates or incidence of SCD and to analyze continuous variables, and 
the chi-square test was used to analyze categorical variables, such 
as baseline characteristics. A multinomial logistic regression model 
was used to analyze the relationship between improvement of LV 
systolic function and multiple factors. All reported p were 2-tailed. 
Statistical Package for the Social Sciences version 17.0 was used for 
all statistical analyses and p<0.05 was considered statistically sig-
nificant. 
Results
Clinical characteristics of the study population
The baseline characteristics of both groups are presented in Table 
1. The NICMP group was younger (56±14 vs. 65±11 years, p<0.001) 
and had more female patients than the ICMP group (42% vs. 29%, 
p=0.032). The NICMP group had a higher prevalence of AF and val-
vular heart disease than the ICMP group, whereas the ICMP group 
had more hypertension, diabetes mellitus, and renal disease. ICMP 
patients received HMG-CoA reductase inhibitors and anti-platelet 
therapy more frequently than the NICMP patients, whereas digitalis, 
thiazide and anti-coagulation therapy were prescribed more often 
in the NICMP group. Among 275 objective patients, 189 did not take 
any beta-blockers. Only 13% of these patients had contraindications 
such as chronic obstructive pulmonary disease or asthma (n=18, 
10%), bradycardia or sick sinus syndrome (n=2, 1%), hypotension 
(n=2, 1%), or intolerance (n=2, 1%).
The ischemic cardiomyopathy group had a similar incidence
of sudden cardiac death, but a higher all-cause mortality 
rate than the non-ischemic cardiomyopathy group
During the 40 months follow-up period, nearly one-third of the to-
Table 1. Baseline clinical characteristics 
All patients (n=275) NICMP (n=144) ICMP (n=131) p*
Age (mean±SD, years) 61±13 56±14 65±11 <0.001
Male sex, n (%) 177 (64) 84 (58) 93 (71) 0.032
F/U duration (mean±SD, months) 40±17 42±17 38±16 0.039
EF (%) 24±5 24±5 24±4 0.882
Underlying disease, n (%)
    Atrial fibrillation  80 (29) 62 (43) 18 (14) <0.001
    HTN on treatment  102 (37) 38 (26) 64 (49) <0.001
    DM  108 (39) 40 (28) 68 (52) <0.001
    Renal disease  60 (22) 21 (15) 39 (30) 0.003
    Valvular heart disease  33 (12) 26 (18) 8 (6) 0.005
Medications, n (%)
    Beta-blockers  86 (31) 42 (29) 42 (32) 0.694
    ACEI or ARB  243 (88) 127 (88) 116 (89) 1.000
    Amiodarone  25 (9) 15 (10) 10 (8) 0.530
    Digitalis  139 (51) 85 (59) 54 (41) 0.004
    HMG-CoA reductase inhibitor  89 (32) 23 (16) 67 (51) <0.001
    Potassium sparing diuretics  120 (44) 70 (49) 50 (38) 0.089
    Loop diuretics  149 (54) 80 (56) 69 (53) 0.716
    Thiazide  142 (52) 85 (59) 57 (44) 0.011
    Anti-platelet drug  160 (58) 48 (37) 113 (86) <0.001
    Anticoagulation therapy  66 (24) 48 (33) 18 (14) <0.001
*ICMP vs. NICMP. NICMP: non-ischemic cardiomyopathy, ICMP:  ischemic cardiomyopathy, SD: standard deviation, F/U: follow-up, EF: ejection fraction, HTN: hy-
pertension, DM: diabetes mellitus, ACEI: angiotensin-converting-enzyme inhibitor, ARB: angiotensin II receptor blocker, HMG-CoA: hydroxymethylglutaryl CoA176  Implantable Cardioverter Defibrillator Implantation
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tal population (80 patients, 29%) died from all causes of death. The 
causes of death in these 80 cases were obtained from hospital re-
cords (n=28), telephone contact with family members (n=18), or 
databases obtained from the NSO (n=34). SCD could be identified 
from in-hospital records (n=11), telephone contact with family mem-
bers (n=10) and databases obtained from the NSO (n=2). Causes of 
death are summarized in Table 2. The all-cause mortality rate of the 
ICMP group was higher than that of the NICMP group (40% vs. 
19%, p<0.001) (Fig. 1). However, there was no statistical difference 
in total cardiac death (21% vs. 15%, p=0.082), SCD (10% vs. 7%, p= 
0.272), non-SCD (5% vs. 3%, p=0.194), or unclassified cardiac death 
(6% vs. 5%, p=0.502) between the ICMP and NICMP groups. The 
ICMP group died of non-cardiac causes more frequently than the 
NICMP group (18% vs. 4%, p<0.001). There were 24 non-cardiac 
deaths in the ICMP group, including deaths from chronic renal fail-
ure with end-stage renal disease (n=8), complications of diabetes 
mellitus (n=5), systemic infection (n=3), malignancy (n=5), inter-
stitial lung disease (n=1), cerebral infarction (n=1), and toxic hepa-
titis (n=1). In the NICMP group, non-cardiac deaths (n=6) were due 
to diabetic complications (n=3), chronic renal failure (n=1), and 
malignancy (n=2). 
Ischemic cardiomyopathy and old age were independent 
predictors for all-cause death
In a univariate analysis for all-cause death in the total population, 
old age {>70 years old, HR 2.16 (95% CI 1.37-3.39), p=0.001}, ICMP 
{HR 2.42 (1.52-3.85), p<0.001}, and potassium-sparing diuretics 
{HR 0.58 (0.36-0.93), p=0.025} were significant prognostic factors 
(Table 3). However, chronic kidney disease {HR 1.60 (0.99-2.59), p= 
0.053} and beta-blockers {HR 0.65 (0.39-1.08), p=0.080} did not 
show statistical significance as prognostic factors. In a multivariate 
Cox regression model, ICMP {HR 2.91 (1.52-5.59), p=0.001} and old 
age {>70 years old, HR 1.89 (1.13-3.15), p=0.015} were independent 
predictors for all-cause mortality. Valvular heart disease {HR 2.00 
(0.93-4.33), p=0.078}, potassium-sparing diuretics {HR 0.59 (0.35-
1.01), p=0.053}, and loop diuretics {HR 1.59 (0.97-2.61), p=0.069} 
were likely to be prognostic factors for all-cause mortality. There 
were no independent predictors for SCD (Table 4). 
Ischemic cardiomyopathy {HR 6.18 (1.89-20.24), p=0.003}, ch-
ronic kidney disease {HR 2.80 (1.13-6.94), p=0.026}, HMG-CoA re-
Table 2. Causes of deaths
N (%) Total population (n=275) NICMP (n=144) ICMP (n=131) p* 
All-cause death 80 (29) 27 (19) 53 (40) <0.001
Cardiac death 49 (18) 21 (15) 28 (21) 0.082
    Sudden cardiac death 23 (8) 10 (7) 13 (10) 0.272
    Non-sudden cardiac death 11 (4) 4 (3) 7 (5) 0.194
    Unclassified cardiac death 15 (5) 7 (5) 8 (6) 0.502
Non-cardiac death 30 (11) 6 (4) 24 (18) <0.001
Unknown cause 1 (0) 0 1 (1)
*ICMP vs. NICMP, p estimated by Kaplan-Meier curve and log-rank test. NICMP: non-ischemic cardiomyopathy, ICMP: ischemic cardiomyopathy
Fig. 1. Kaplan-Meier curves of survival. A: probability of survival (death from any cause). B: cumulative probability of sudden cardiac death. ICMP: ischemic car-
diomyopathy, NICMP: non-ischemic cardiomyopathy.
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ductase inhibitors {HR 0.29 (0.11-0.76), p=0.012}, and digitalis {HR 
2.05 (1.01-4.17), p=0.047} were independent predictors for non-
cardiac death.
Subgroup analysis for cause of death 
A univariate analysis of the ICMP group showed that anti-plate-
let medication, valvular heart disease, and digitalis showed statisti-
cal significance for all-cause death (p=0.036, p=0.023, and p=0.042, 
respectively). In a multivariate Cox regression analysis of the ICMP 
group, old age {>70 years old, HR 2.27 (1.15-4.47), p=0.018}, anti-
platelet medication {HR 0.41 (0.18-0.92), p=0.030}, and revasculariz-
ation therapy {HR 2.23 (1.05-4.73), p=0.036} were independent 
prognostic factors for all-cause mortality (Table 5). However, re-
vascularization therapy was not a significant predictor for other 
causes of death, such as total cardiac death, SCD, non-SCD, or non-
cardiac death. In 82 patients with revascularization therapy, 45 pa-
tients had undergone PCI therapy, 25 patients in the CABG and 10 
patients in both the PCI and CABG, and 2 patients in thrombolysis. 
According to the method used for revascularization therapy, there 
was no method which showed statistical significance related to all-
caused death. 
The ICMP group was subdivided according to specified anti-plate-
let drugs: no anti-platelet drug (n=18, 14%), aspirin alone (n=62, 
47%), clopidogrel alone (n=7, 5%), aspirin and clopidogrel (n=42, 
32%), aspirin and cilostazol (n=1, 1%), and triple anti-platelet medic-
ation (aspirin, clopidogrel, and cilostazol, n=1, 1%). In a Kaplan-Mei-
er pair-wise comparison according to the anti-platelet medication, pa-
tients with single or multiple anti-platelet medication showed better 
survival than those without anti-platelet medication, but this find-
ing was not statistically significant (p=0.051 and p=0.057, respec-
tively). However, there was no significant difference in prognosis be-
tween use of a single drug and use of multiple drugs (p=0.830). There 
was no independent predictor for SCD in the ICMP group. For non-
cardiac death, chronic kidney disease {HR 4.29 (1.53-11.97), p=0.006} 
and HMG-CoA reductase inhibitors {HR 0.25 (0.08-0.85), p=0.025} 
were independent predictors. 
In the NICMP group, valvular heart disease {HR 4.92 (1.47-16.51), 
p=0.010} and potassium sparing diuretics {HR 0.31 (0.11-0.86), p= 
Table 3. Predictors of all-cause mortality
Univariate analysis Multivariate analysis*
Hazard ratio (95% CI) p Hazard ratio (95% CI) p
Age  >70 years 2.155 (1.369-3.393) 0.001 1.887 (1.129-3.153) 0.015
Male sex  1.033 (0.652-1.635) 0.891 0.937 (0.570-1.542) 0.799
EF  1.000 (0.952-1.050) 0.996 0.991 (0.938-1.048) 0.754
ICMP 2.419 (1.521-3.849) <0.001 2.911 (1.516-5.588) 0.001
Underlying disease
    Atrial fibrillation  0.904 (0.549-1.488) 0.692 1.047 (0.563-1.948) 0.884
    HTN on treatment  1.060 (0.674-1.667) 0.802 0.896 (0.529-1.520) 0.685
    DM 1.153 (0.740-1.796) 0.530 0.963 (0.552-1.678) 0.894
    Renal disease  1.604 (0.994-2.589) 0.053 1.487 (0.844-2.620) 0.170
    Valvular heart disease  1.565 (0.847-2.892) 0.153 2.001 (0.925-4.327) 0.078
Medications
    Beta-blockers  0.646 (0.386-1.081) 0.097 0.746 (0.429-1.295) 0.298
    ACEI or ARB  0.663 (0.359-1.225) 0.189 0.635 (0.327-1.234) 0.180
    Amiodarone  0.478 (0.175-1.307) 0.151 0.472 (0.168-1.332) 0.156
    Digitalis 1.110 (0.716-1.721) 0.642 1.494 (0.873-2.556) 0.143
    HMG-CoA reductase inhibitor  1.053 (0.665-1.667) 0.826 0.830 (0.489-1.408) 0.490
    Potassium sparing diuretics  0.582 (0.363-0.934) 0.025 0.589 (0.345-1.007) 0.053
    Loop diuretics  1.407 (0.899-2.201) 0.136 1.586 (0.965-2.608) 0.069
    Thiazide  0.670 (0.431-1.041) 0.075 0.796 (0.490-1.295) 0.359
    Anti-platelet drug  1.373 (0.867-2.175) 0.177 0.836 (0.452-1.546) 0.568
    Anticoagulation therapy 0.860 (0.497-1.488) 0.590 1.130 (0.530-2.406) 0.752
*Adjusted with age (>70 years old), sex, EF, ICMP, atrial fibrillation, HTN, DM, renal disease, valvular heart disease, beta-blockers, ACEI or ARB, amiodarone, 
digitalis, HMG-CoA reductase inhibitor, potassium sparing diuretics, loop diuretics, thiazide, anti-platelet drug, and anticoagulation. CI: confidence interval, 
EF: ejection fraction, ICMP: ischemic cardiomyopathy, HTN: hypertension, DM: diabetes mellitus, ACEI: angiotensin-converting-enzyme inhibitor, ARB: an-
giotensin II receptor blocker, HMG-CoA: hydroxymethylglutaryl CoA178  Implantable Cardioverter Defibrillator Implantation
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0.025} were prognostic factors of all-cause mortality; however, th-
ere were no independent prognostic factors for SCD.
Improvement of left ventricular systolic function during 
follow-up period
During the follow-up, 237 patients (131 patients in the NICMP gr-
oup) had undergone follow-up echocardiography evaluation. Mean 
LVEF during follow-up was 28±8%. There was no significant differ-
ence in the change of LVEF during follow-up in both the NICMP and 
the ICMP group (5±9% vs. 5±7%, p=0.670). Ninety-two (39%) pa-
tients showed improvement in LV systolic function compared to 
baseline (the change in LVEF: 65±41%, absolute change: 13±6%). 
The number of patients in the NICMP group who had >25% impro-
vement in LVEF was greater than the number in the ICMP group, 
but the difference was not statistically significant (42% vs. 35%, 
p=0.286). Patient characteristics were analyzed to identify those 
who showed improvement of >25% in LV systolic function com-
pared to the baseline (Table 6). The improved group had a lower EF 
at baseline (22±5% vs. 25±4%, p<0.001) and took anti-platelet 
medication less frequently (51% vs. 66%, p=0.029). 
Other baseline characteristics such as ischemic cause, medica-
tion, and other comorbidities were similar. Despite improvement of 
LV systolic dysfunction, there was no significant difference in clini-
cal outcomes, i.e. all-cause mortality, SCD, total cardiac death, or 
non-cardiac death according to LV systolic improvement (all 
p>0.05). 
Comparison of survival with Western population studies
To test whether the survival of the Korean population with severe 
heart failure was different from that of the Western population with 
heart failure, the clinical outcomes were compared with 2 well-
known Western heart failure studies.
5)6) The ICMP group was com-
pared to the MADIT-II conventional group (n=490). There were no 
significant differences in age and mean LVEF, whereas the Korean 
ICMP group had fewer male patients (71% vs. 85%, p=0.001). In 
addition, beta-blockers (32% vs. 70%, p<0.001) and HMG-CoA re-
ductase inhibitors (51% vs. 64%, p=0.006) were prescribed less of-
ten in the Korean ICMP group, and ACEI or ARB were prescribed 
Table 4. Predictors of sudden cardiac death 
Univariate analysis Multivariate analysis*
Hazard ratio (95% CI) p Hazard ratio (95% CI) p
Age  >70 years 2.724 (1.192-6.224) 0.017 2.033 (0.789-5.238) 0.142
Male sex  1.055 (0.447-2.488) 0.903 0.790 (0.310-2.013) 0.622
EF  1.022 (0.929-1.125) 0.656 1.015 (0.910-1.132) 0.792
ICMP 1.583 (0.693-3.617) 0.276 1.498 (0.449-4.999) 0.511
Underlying disease
    Atrial fibrillation  1.339 (0.568-3.160) 0.505 2.286 (0.726-7.202) 0.158
    HTN on treatment  0.931 (0.394-2.197) 0.870 1.171 (0.443-3.098) 0.750
    DM  0.675 (0.278-1.641) 0.386 0.543 (0.188-1.571) 0.260
    Renal disease  0.790 (0.268-2.321) 0.667 0.662 (0.202-2.171) 0.496
    Valvular heart disease  1.304 (0.387-4.389) 0.669 2.288 (0.458-11.42) 0.313
Medications
    Beta-blockers  0.583 (0.216-1.570) 0.286 0.536 (0.186-1.544) 0.248
    ACEI or ARB  0.552 (0.188-1.627) 0.281 0.731 (0.219-2.439) 0.611
    Amiodarone  0.880 (0.206-3.756) 0.863 0.927 (0.199-4.323) 0.923
    Digitalis  0.640 (0.277-1.479) 0.296 0.618 (0.225-1.700) 0.351
    HMG-CoA reductase inhibitor  1.051 (0.445-2.479) 0.910 1.079 (0.397-2.935) 0.881
    Potassium sparing diuretics  0.457 (0.203-1.026) 0.058 0.406 (0.135-1.218) 0.108
    Loop diuretics 1.604 (0.763-3.373) 0.213 1.366 (0.559-3.339) 0.494
    Thiazide 0.628 (0.305-1.294) 0.208 0.659 (0.264-1.647) 0.372
    Anti-platelet drug  1.146 (0.496-2.650) 0.750 0.974 (0.313-3.027) 0.963
    Anticoagulation therapy 0.716 (0.243-2.106) 0.544 0.518 (0.107-2.501) 0.413
*Adjusted with age (>70 years old), sex, EF, ICMP, atrial fibrillation, HTN, DM, renal disease, valvular heart disease, beta-blockers, ACEI or ARB, amiodarone, 
digitalis, HMG-CoA reductase inhibitor, potassium sparing diuretics, loop diuretics, thiazide, anti-platelet drug, and anticoagulation. CI: confidence interval, 
EF: ejection fraction, ICMP: ischemic cardiomyopathy, HTN: hypertension, DM: diabetes mellitus, ACEI: angiotensin-converting-enzyme inhibitor, ARB: an-
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more frequently (89% vs. 72%, p<0.001). In the 2-year mortality ob-
tained from the Kaplan-Meier analysis, the ICMP group had a simi-
lar all-cause mortality (20% vs. 20%) and incidence of SCD (7% vs. 
10%) compared to the MADIT-II conventional therapy group (re-
spectively, all p>0.05) (Fig. 2). 
The NICMP group was compared to the DEFINITE standard thera-
py group (no ICD, n=229). There was no significant difference in age 
and mean LVEF compared to the DEFINITE standard therapy group, 
whereas the percentage of males in the NICMP group was less than 
that of the DEFINITE standard therapy group (58% vs. 70%, p= 
0.026), and AF in the NICMP group was more frequent (43% vs. 26%, 
p=0.001). Beta-blockers (29% vs. 84%, p<0.001) were prescribed less 
in the Korean NICMP group. The probability of survival and SCD were 
similar in the Korean NICMP group and the DEFINITE standard th-
erapy group (13% vs. 17%; 6% vs. 6%, all p>0.05) (Fig. 3). 
Discussion 
The present study showed several findings as follows: 1) ICMP 
patients had a poorer prognosis than NICMP patients, despite sim-
ilar LV systolic dysfunction; 2) the incidence of SCD was similar in 
both groups; and 3) both ICMP and NICMP groups had comparable 
risks of SCD; similar to results in previous Western population 
studies. 
Prognosis of Korean heart failure population
The mortality rate in our study population was 15% for 2 years 
and 29% for 40 months of follow-up. SCD accounted for nearly 
33% of total deaths. When compared with previous studies, the 
mortality rate in our study was similar to the previous ones.
13) Pa-
tients in previous studies, including those who were admitted for 
heart failure, had a 2-year cumulative survival rate of 80.1%.
13) In ad-
Table 5. Multivariate analysis of all-cause mortality and sudden cardiac death in ICMP
All-cause mortality* Sudden cardiac death
†
Hazard ratio (95% CI) p Hazard ratio (95% CI) p
Age  >70 years 2.271 (1.154-4.469) 0.018 2.031 (0.500-8.257) 0.322
Male sex  0.692 (0.361-1.328) 0.268 0.471 (0.124-1.784) 0.268
EF  0.975 (0.907-1.048) 0.493 0.987 (0.839-1.160) 0.871
Revascularization 2.231 (1.053-4.729) 0.036 2.755 (0.637-11.92) 0.175
Previous myocardial infarction 0.776 (0.392-1.537) 0.467 0.857 (0.185-3.969) 0.844
Underlying disease
    Atrial fibrillation  0.581 (0.222-1.523) 0.270 1.312 (0.168-10.24) 0.796
    HTN on treatment  0.697 (0.338-1.438) 0.329 1.065 (0.259-4.377) 0.930
    DM  1.623 (0.752-3.504) 0.218 1.205 (0.286-5.073) 0.799
    Renal disease  1.234 (0.599-2.540) 0.568 0.281 (0.049-1.625) 0.156
    Valvular heart disease  1.958 (0.617-6.214) 0.254
Medications
    Beta-blockers  0.869 (0.417-1.812) 0.709 1.579 (0.377-6.615) 0.532
    ACEI or ARB 0.664 (0.278-1.584) 0.356 1.183 (0.137-10.22) 0.878
    Amiodarone  0.636 (0.181-2.239) 0.481 0.844 (0.083-8.606) 0.886
    Digitalis 2.042 (1.002-4.161) 0.049 1.452 (0.327-6.449) 0.624
    HMG-CoA reductase inhibitor  0.669 (0.353-1.271) 0.220 0.599 (0.154-2.322) 0.458
    Potassium sparing diuretics 0.765 (0.370-1.583) 0.471 0.425 (0.080-2.256) 0.315
    Loop diuretics  1.243 (0.641-2.409) 0.519 0.996 (0.257-3.854) 0.995
    Thiazide  0.893 (0.463-1.720) 0.735 0.988 (0.274-3.560) 0.986
    Anti-platelet drug  0.406 (0.180-0.917) 0.030 0.371 (0.071-1.950) 0.241
    Anticoagulation therapy  2.644 (0.902-7.752) 0.077 0.723 (0.042-12.59) 0.824
*Adjusted with age (>70 years old), sex, EF, revascularization, previous myocardial infarction, atrial fibrillation, HTN, DM, renal disease, valvular heart disease, 
beta-blockers, ACEI or ARB, amiodarone, digitalis, HMG-CoA reductase inhibitor, potassium sparing diuretics, loop diuretics, thiazide, anti-platelet drug, and 
anticoagulation. 
†Adjusted with age (>70 years old), sex, EF, revascularization, previous myocardial infarction, atrial fibrillation, HTN, DM, renal disease, beta-
blockers, ACEI or ARB, amiodarone, digitalis, HMG-CoA reductase inhibitor, potassium sparing diuretics, loop diuretics, thiazide, anti-platelet drug, and an-
ticoagulation. CI: confidence interval, EF: ejection fraction, ICMP: ischemic cardiomyopathy, HTN: hypertension, DM: diabetes mellitus, ACEI: angiotensin-
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dition, Chinese patients with MADIT-II criteria had an all-cause 
death rate of 26%, with a mean of 35 months for a follow-up pe-
riod.
10) The all-cause mortality rate for the control group in the MA-
DIT-II study was 20% during 20 months follow-up.
4) However, Jap-
anese patients with similar MADIT-II criteria had a lower mortality 
rate than in previous reports and our results, and they reported a 
rate of 17% for death events, with an average of 37 months for the 
follow-up period.
9) The Japanese paper reported a lower rate for 
SCD than the previous Chinese paper, MADIT-II, and our study.
5)9)10) 
These differences could be explained by the difference in preval-
ence of the patients with NYHA Fc I. Our study included only those 
patients with NYHA Fc II or III, whereas the Japanese study con-
sisted of 79% NYHA Fc I patients.
9) In addition, the Chinese study 
and MADIT-II study included fewer patients who were NYHA Fc I 
patients (27% and 39%, respectively).
4)5)10) Advanced NYHA Fc 
might be an important risk factor for SCD in this population.
14)15) 
Based on these results, we should be careful to recommend prophyl-
actic ICD implantation in those patients with good functional status. 
In comparison to the MADIT-II and DEFINITE studies, the number 
of prescriptions for beta-blockers was lower in our study. Although 
13% of patients had contraindications for beta-blocker therapy, 
there is a need to investigate the exact reason why a beta-blocker 
was not prescribed in the retrospective study design. The Japanese 
heart failure study showed a prescription rate for beta-blockers si-
milar to our study.
9) Although we do not have statistical data on the 
prescription rate of beta-blockers in Korea between 2003 and 2006, 
Table 6. Baseline clinical characteristics and cause of death according to LVEF improvement
Patients with LVEF improvement (n=92) Patients without LVEF improvement (n=145) p*
Age (mean±SD, years) 58±12 60±14 0.131
Male sex (%) 55 (60) 96 (66) 0.334
F/U duration (mean±SD, months) 40±15 42±17 0.466
EF (%) 22±5 25±4 <0.001
The number of F/U echocardiography 2±1 2±1 0.266
ICMP (%) 37 (40) 69 (48) 0.286
Underlying disease (%)
    Atrial fibrillation 33 (36) 35 (24) 0.057
    HTN on treatment 37 (40) 57 (39) 0.893
    DM 38 (41) 55 (38) 0.682
    Renal disease 18 (20) 35 (24) 0.429
    Valvular heart disease 8 (9) 20 (14) 0.303
Medications (%)
    Beta-blockers 35 (38) 42 (29) 0.157
    ACEI or ARB 81 (88) 128 (88) 1.000
    Amiodarone 9 (10) 16 (11) 0.831
    Digitalis 47 (51) 75 (52) 1.000
    HMG-CoA reductase inhibitor 33 (36) 48 (33) 0.676
    Potassium sparing diuretics 46 (50) 61 (42) 0.284
    Loop diuretics 50 (54) 84 (58) 0.594
    Thiazide 52 (57) 80 (55) 0.894
    Anti-platelet drug 47 (51) 96 (66) 0.029
    Anticoagulation therapy 25 (27) 33 (23) 0.535
Death (%)
†
    All-cause mortality (n) 21 (23) 39 (27) 0.669
    Sudden cardiac death (n) 3 (3)   12 (8) 0.148
    Total cardiac death (n) 11 (12) 24 (17) 0.461
    Non-cardiac death (n) 9 (10) 15 (10) 0.946
LVEF improvement: improvement of >25% in the LV systolic function compared to the baseline. *p estimated by chi-square methods except classification of 
deaths, 
†p estimated by Kaplan-Meier curve and log-rank test. ICMP: ischemic cardiomyopathy, SD: standard deviation, F/U: follow-up, EF: ejection fraction, 
HTN: hypertension, DM: diabetes mellitus, ACEI: angiotensin-converting-enzyme inhibitor, ARB: angiotensin II receptor blocker, LVEF: left ventricular ejec-
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there is one study that does address this question.
16) The study fo-
und that even tertiary hospitals prescribed beta-blockers for <20% 
of patients with heart failure and for 30% of patients with ischemic 
heart disease. Considering that our study included heart failure pa-
tients between 2003 and 2006, the prescription rate of beta-blockers 
might be lower than that in current practice, but not so different 
from other hospitals in a similar period. The Study of HF Awareness 
and Perception in Europe (SHAPE), which was performed in the early 
2000s, analyzed the low prescription pattern of beta-blockers for 
heart failure patients in the real world.
17) According to the SHAPE 
study, in mild to moderate stable HF patients without signs of fluid 
retention, only 25% of cardiologists started a beta-blocker with 
ACEI. Few cardiologists started therapy by using a beta-blocker only. 
Although there was no contraindication to beta-blocker therapy, 
elderly patients or those with ACEI or on diuretic therapy were less 
likely to receive a beta-blocker. Considering the high prescription 
rates for ACEI or ARB in our study, additional beta-blocker therapy 
might not be considered for stable heart failure patients. In our 
study, beta-blockers were not a statistically significant prognostic 
factor for all-cause mortality, SCD, or non-cardiac death, but the re-
sults were close to being significant {HR 0.65 (0.39-1.08), p=0.097}. 
Updated prescription rates for beta-blockers and their prognostic 
effect in a Korean heart failure population should be evaluated in 
a future study. 
Similar criteria for prophylactic implantable cardioverter 
defibrillator implantation in both ischemic cardiomyopathy 
and non-ischemic cardiomyopathy
In this study, the mortality rate of the ICMP group was higher 
than that of the NICMP group. One of the explanations could be the 
difference in baseline characteristics. The ICMP group was older and 
frequently had more co-morbidities such as renal failure, hyper-
tension, and diabetes, which are important prognostic factors. Dia-
betes and chronic kidney disease are well known to be poor prog-
nostic factors of heart failure and risk factors for ischemic heart 
disease.
18-21) HMG-CoA reductase inhibitors are known to reduce 
mortality among patients with severe heart failure and to lower 
the mortality in patients with hemodialysis.
22)23) In a Cox regression 
analysis for non-cardiac death, chronic kidney disease was associ-
ated with a poor prognosis, whereas HMG-CoA reductase inhibitors 
Fig. 2. Comparison of survival between ICMP group and MADIT-II conventional therapy group. A: probability of survival (death from any cause). B: cumulative prob-
ability of sudden cardiac death. ICMP: ischemic cardiomyopathy, CTx: conventional treatment, MADIT-II: Multicenter Automatic Defibrillator Implantation Trial II.
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were found to be related to a reduced risk of mortality. Therefore, 
a higher prevalence of comorbidities could increase the risk of non-
cardiac death, which could be an important reason for the increased 
all-cause mortality in the ICMP group. Previous studies reported a 
difference in survival between NICMP and ICMP patients.
11) Alth-
ough NICMP patients were younger, patients with ICMP had poorer 
clinical outcomes than the NICMP patients.
11)13) NICMP patients sh-
owed a greater improvement in symptoms and left ventricular func-
tion during follow-up.
11) We found that the NICMP group was more 
likely to show improvement in LV systolic function than the ICMP 
group during follow-up, even though the difference was not sta-
tistically significant. Also, the improvement of LV systolic function 
was not a prognostic factor for all-cause mortality, SCD, or non-car-
diac death.
The risk of SCD in our study group was not lower than in previous 
Western population studies. Therefore, the current guidelines for 
prophylactic ICD implantation based on Western populations are 
acceptable in Korean patients with heart failure.
In conclusion, the risk of SCD in Korean patients with severe he-
art failure and fulfill the prophylactic ICD implantation criteria is 
comparable to those of other Asian studies and Western popula-
tion studies. This suggests that prophylactic ICD implantation in this 
population might provide a beneficial effect similar to that found 
in other Asian and Western populations.
Study limitations
This study was conducted at a single tertiary center and was a 
retrospective study, so there is a limitation when extrapolating these 
results to the entire Korean population. For those who died out-of-
hospital, the cause of death was classified based on the death cer-
tificates and telephone contact with family members. There might 
be a possibility that some SCD events could have been misclassified 
as non-SCD or non-cardiac death, which could underestimate the 
SCD risk in this population. Also, there could be recall bias of fami-
ly members. The study population was smaller than the study pop-
ulations in the MADIT-II and DEFINITE studies. However, considering 
the similar reports from other Asian countries, the number of sub-
jects in our study was comparable. The prescriptions for beta-block-
ers and HMG-CoA reductase inhibitors were less than in previous 
reports, such as MADIT-II and DEFINITE.
5)6) However, the prescription 
of beta-blockers was not lower than the average prescription rate 
in Korean patients with heart failure.
16) We used the inclusion crite-
ria described in the Korean medical reimbursement guideline; there-
fore, the conventional group in the DEFINITE trial had less severe 
inclusion criteria than our NICMP group. However, there is no large-
scale trial which had the same inclusion criteria as our study. Al-
though the conventional group in the DEFINITE trial included those 
with 31-36% of LVEF, there was no significant difference in the 
mean LVEF compared to our NICMP group. In addition, the clinical 
outcome was similar in the 2 groups.
Acknowledgments
This study was supported by grant no 04-2010-1140 from the 
SNUH Research Fund.
References
1. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an im-
planted defibrillator in patients with coronary disease at high risk for 
ventricular arrhythmia: Multicenter Automatic Defibrillator Implan-
tation Trial Investigators. N Engl J Med 1996;335:1933-40.
2. Sohn JW, Shin DG, Kim DH, et al. Non-invasive parameters, including 
a low left ventricular ejection fraction, for predicting sudden cardiac 
death in Korean post myocardial infarction patients. Korean Circ J 2006; 
36:431-6.
3. Vlay SC. The ACC/AHA/HRS 2008 guidelines for device-based therapy 
of cardiac rhythm abnormalities: their relevance to the cardiologist, 
internist and family physician. J Invasive Cardiol 2009;21:234-7.
4. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defi-
brillator in patients with myocardial infarction and reduced ejection 
fraction. N Engl J Med 2002;346:877-83.
5. Greenberg H, Case RB, Moss AJ, Brown MW, Carroll ER, Andrews ML. 
Analysis of mortality events in the Multicenter Automatic Defibrilla-
tor Implantation Trial (MADIT-II). J Am Coll Cardiol 2004;43:1459-65.
6. Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implan-
tation in patients with nonischemic dilated cardiomyopathy. N Engl J 
Med 2004;350:2151-8.
7. Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 
guidelines for device-based therapy of cardiac rhythm abnormalities: 
a report of the American College of Cardiology/American Heart Associ-
ation Task Force on Practice Guidelines (Writing Committee to revise 
the ACC/AHA/NASPE 2002 guideline update for implantation of car-
diac pacemakers and antiarrhythmia devices): developed in collabora-
tion with the American Association for Thoracic Surgery and Society 
of Thoracic Surgeons. Circulation 2008;117:e350-408.
8. Zheng ZJ, Croft JB, Giles WH, Mensah GA. Sudden cardiac death in the 
United States, 1989 to 1998. Circulation 2001;104:2158-63.
9. Tanno K, Miyoshi F, Watanabe N, et al. Are the MADIT II criteria for ICD 
implantation appropriate for Japanese patients? Circ J 2005;69:19-22.
10.   Siu CW, Pong V, Ho HH, et al. Are MADIT II criteria for implantable car-
dioverter defibrillator implantation appropriate for Chinese patients? 
J Cardiovasc Electrophysiol 2010;21:231-5.
11. Ng AC, Sindone AP, Wong HS, Freedman SB. Differences in manage-
ment and outcome of ischemic and non-ischemic cardiomyopathy. 
Int J Cardiol 2008;129:198-204.
12. Solomon SD, Zelenkofske S, McMurray JJ, et al. Sudden death in pa-
tients with myocardial infarction and left ventricular dysfunction, heart 
failure, or both. N Engl J Med 2005;352:2581-8.
13.   Han SW, Ryu KH, Chae SC, et al. Multicenter analysis of clinical char-183 JiYeong Kim, et al.
http://dx.doi.org/10.4070/kcj.2012.42.3.173 www.e-kcj.org
acteristics and prognostic factors of patients with congestive heart 
failure in Korea. Korean Circ J 2005;35:357-61.
14.   Cesario DA, Dec GW. Implantable cardioverter-defibrillator therapy in 
clinical practice. J Am Coll Cardiol 2006;47:1507-17.
15. The Multicenter Postinfarction Research Group. Risk stratification and 
survival after myocardial infarction. N Engl J Med 1983;309:331-6.
16. Sung YN, Jang SM, Lim DH, Shin SY, Song HJ, Lee SH. Prescribing Pat-
terns of Antihypertensive Drugs by Outpatients with Hypertension in 
2007. Korean J Clin Pharmacol 2009;19:167-79.
17.   Remme WJ, McMurray JJ, Hobbs FD, et al. Awareness and perception 
of heart failure among European cardiologists, internists, geriatri-
cians, and primary care physicians. Eur Heart J 2008;29:1739-52.
18.   Doehner W, Rauchhaus M, Ponikowski P, et al. Impaired insulin sensi-
tivity as an independent risk factor for mortality in patients with stable 
chronic heart failure. J Am Coll Cardiol 2005;46:1019-26.
19.   McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW. Renal insuffici-
ency and heart failure: prognostic and therapeutic implications from 
a prospective cohort study. Circulation 2004;109:1004-9.
20.   Ahmed A, Rich MW, Sanders PW, et al. Chronic kidney disease associ-
ated mortality in diastolic versus systolic heart failure: a propensity 
matched study. Am J Cardiol 2007;99:393-8.
21. Bonow RO, Smaha LA, Smith SC Jr, Mensah GA, Lenfant C. World Heart 
Day 2002: the international burden of cardiovascular disease: respond-
ing to the emerging global epidemic. Circulation 2002;106:1602-5.
22.   Mason NA, Bailie GR, Satayathum S, et al. HMG-coenzyme a reduc-
tase inhibitor use is associated with mortality reduction in hemodialy-
sis patients. Am J Kidney Dis 2005;45:119-26.
23. Mozaffarian D, Nye R, Levy WC. Statin therapy is associated with lower 
mortality among patients with severe heart failure. Am J Cardiol 2004; 
93:1124-9.